Clinical Trial Search

Primary: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve of Tirzepatide in Breastmilk From Zero to Infinity (AUC [0-∞]) — NA nanogram*hours per milliliter…

Primary: Safety of TNP-2092 by Assessment of the Number of Participants With Adverse Events (AEs) — 0; 1; 2; 1 Participants

Primary: Number of Participants With Adverse Events (AEs) — 4; 3 Participants

Primary: Percentage Change From Baseline in Forearm Blood Flow in Response to Increasing Intraarterial Doses of C21 — 27.8; 17.2; 37.0; 28.5 percentage of change from baseline

Primary: Pharmacokinetics (PK): Area Under the Concentration-time Curve, From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Selpercatinib in Plasma (Part…

Primary: Change From Baseline in QT Interval Corrected for Heart Rate (QTc) Following MK-8189 Treatment — 4.31; -1.38; -0.61; -1.13 ΔQTcF (msec)

Primary: Explicit Memory Performance — 1.16; .51; 1.04; .98 units on a scale

Primary: Serum Concentrations of AZD7442 — 86.32; 91.88; 92.49; 84.69 Microgram per milliliter (ug/mL)

Primary: Number of Treatment Emergent Adverse Events — 6; 1; 7 Participants

Primary: Number of Treatment Emergent Adverse Events — 0; 17; 2; 4 Participants

Primary: To Determine, During the Dose Escalation Phase, the Recommended Dose of PCLX-001 for the Dose Expansion Phase of the Trial. — 210 mg

Primary: Number of Participants With Solicited Injection Site Adverse Events — 1; 0 Participants

Primary: MTD/RP2D Determination Cohort A — 0; 0; 0 Participants

Primary: Safety and Tolerability of Varying Doses of Intratumoral Ad-RTS-hIL-12 and Oral Veledimex Doses in Subjects With Recurrent or Progressive Glioblastoma or Grade III…

Primary: Emax — 0.201 Maximum clearance rate (1/hour)